Kevin Chang
Associé,
Head of our Greater China Healthcare & Life Sciences practice.
À propos de Kevin
Expertise
Kevin Chang is the head of our Greater China Healthcare & Life Sciences practice and a member of our Private Equity practice.
Kevin regularly advises clients on organization, strategy and transformation, as well as both commercial and launch excellence. His recent client engagements have involved due diligence and sector screening and review efforts for private equity clients, as well as adjacency and business unit strategy across pharmaceuticals and biotechnology.
While with the firm, Kevin has led a commercial excellence exercise for one of the world's leading IVD manufacturers, which doubled the company’s business in China in 5 years.
He is also deeply involved with our local pro bono efforts.
Kevin holds a B.A. in Economics from Cornell University.
Recent Insights
- “Why ESG Matters for Medtech in the Asia-Pacific Region,” Rapport, 25 octobre 2023
- “Healthcare and Life Sciences M&A,” M&A Report, 31 janvier 2023, Rapport
- “Healthcare Private Equity in Asia-Pacific: A Multiyear Growth Trajectory ,” Rapport, 15 mars 2022
- “Medtech: The Pandemic Has Expanded Needs and Opportunities ,” Rapport, 15 mars 2022
- “Healthcare IT: Faster, Smarter, Tuned to Value ,” Rapport, 15 mars 2022